Dyadic International INC 8-K filings

Dyadic International announced definitive agreements for a registered direct offering of common stock and a concurrent private placement of warrants, raising approximately $2.9 million.

Dyadic International announced its second-quarter 2026 financial results, highlighting progress in commercialization and partnerships, alongside an increased net loss and reduced cash reserves.

Dyadic International announced that Nasdaq has confirmed the company has regained compliance with listing rules, ensuring its continued listing on the Nasdaq Capital Market.

Dyadic International received a notification from Nasdaq that could lead to the delisting of its securities due to non-compliance with minimum bid price and continued listing standards.

Dyadic International highlights accelerated interest in its C1 biomanufacturing platform driven by Ebola preparedness activities and expanding commercial adoption across various life science sectors.

Dyadic International has entered a research collaboration with Scripps Research to evaluate C1-platform-based antibody and vaccine candidates for hantaviruses.

Dyadic International announced its first quarter 2026 financial results, highlighting significant progress in commercial partnerships and product development, alongside a notable increase in revenue.

Dyadic International, Inc. received a Nasdaq deficiency notice for failing to meet continued listing requirements, including minimum stockholders' equity.

Dyadic International, Inc. announced its 2025 financial results, reporting increased net losses despite significant commercial and strategic partnership advancements.

Dyadic International, Inc. has entered into an At-The-Market Issuance Sales Agreement to sell up to $4.2 million of its common stock through Craig-Hallum Capital Group LLC.

Dyadic International, Inc. amended its Senior Secured Convertible Promissory Note, extending the maturity date to December 31, 2027, and fixing the conversion price at $1.05 per share.

Dyadic International, Inc. received a Nasdaq deficiency notice for failing to maintain the minimum $1 bid price, initiating a 180-day compliance period.

Dyadic International, Inc. announced its third-quarter 2025 financial results, highlighting a strategic shift to commercialization and key advancements in its protein production platforms.

Dyadic International announced it has regained compliance with Nasdaq listing requirements and reported significant milestone achievements in its life sciences and food & nutrition partnerships.

Dyadic International, Inc. amended its Security Agreement, adding CEO Mark Emalfarb's trust as a secured party after his $1 million purchase of a Senior Secured Convertible Promissory Note.

Dyadic International, Inc. announced its second quarter 2025 financial results, highlighting a strategic transformation towards commercial operations and key product advancements.

Dyadic International, Inc. announced the pricing of an underwritten public offering of 6,052,000 shares of common stock at $0.95 per share, expecting to raise approximately $5.3 million in net proceeds for working capital and general corporate purposes.

Dyadic International, Inc. announced a strategic transition from a research-driven organization to a commercially focused enterprise, emphasizing its C1 and Dapibus gene expression platforms.

Dyadic International, Inc. received a Nasdaq deficiency notice for failing to maintain the minimum $1 bid price, compounding an existing non-compliance with the minimum market value of listed securities requirement.

Dyadic International, Inc. announced its strategic rebrand to Dyadic Applied BioSolutions, effective in 30 days, signaling a pivotal shift towards commercializing high-value, non-therapeutic proteins and leveraging its C1 and Dapibus gene expression platforms.

Dyadic International, Inc. has received a deficiency notice from Nasdaq for failing to maintain the minimum $35 million Market Value of Listed Securities, initiating a 180-day compliance period.

Dyadic International, Inc. announced the successful passage of all proposals at its 2025 Annual Meeting of Shareholders, including the re-election of a Class III Director and the ratification of its independent auditor.

Dyadic International, Inc. announced the appointment of Joseph Hazelton as President, a 10% salary increase, and a stock option grant, alongside the adoption of Fourth Amended and Restated Bylaws to align with its strategic shift towards high-demand ancillary protein markets.

Dyadic International announced its Q1 2025 financial results, showcasing progress in commercializing its protein production platforms and expanding its life science and industrial portfolio.

Dyadic International has amended its Senior Secured Convertible Promissory Note agreement, extending the redemption date to December 1, 2026.

Arindam Bose, a director of Dyadic International, Inc., has announced his retirement, effective at the company's annual meeting on June 20, 2025.

Dyadic International announces its 2024 financial results, highlighting revenue growth, progress in commercializing its protein production platforms, and advancements in animal and human health applications.

Dyadic International receives a $4.5 million funding award from CEPI to explore using its C1 fungus technology for faster and more cost-effective protein-based vaccine development.

Dyadic International has received a $3 million grant from the Bill & Melinda Gates Foundation to develop cost-effective monoclonal antibodies for respiratory syncytial virus (RSV) and malaria using its C1 protein production platform.

Dyadic International announced a significant increase in revenue for Q3 2024, driven by licensing fees and milestone payments, alongside advancements in their alternative protein and pharmaceutical collaborations.